Immune checkpoints as therapeutic targets in autoimmunity
Antibodies that block the immune checkpoint receptors PD1 and CTLA4 have revolutionized the treatment of melanoma and several other cancers, but in the process, a new class of drug side effect has emerged-immune related adverse events. The observation that therapeutic blockade of these inhibitory re...
Главные авторы: | Paluch, C, Santos, A, Anzilotti, C, Cornall, R, Davis, S |
---|---|
Формат: | Journal article |
Язык: | English |
Опубликовано: |
Frontiers Media
2018
|
Схожие документы
-
Immune Checkpoints as Therapeutic Targets in Autoimmunity
по: Christopher Paluch, и др.
Опубликовано: (2018-10-01) -
Immune Checkpoints, a Novel Class of Therapeutic Targets for Autoimmune Diseases
по: Yujia Zhai, и др.
Опубликовано: (2021-04-01) -
Combination CD200R/PD-1 blockade in a humanised mouse model
по: Fellermeyer, M, и др.
Опубликовано: (2023) -
Manipulating immune checkpoint signalling pathways with antibodies
по: Paluch, C
Опубликовано: (2019) -
Dermatological Autoimmune Considerations of Immune Checkpoint Therapy
по: Lauren S. Fane, и др.
Опубликовано: (2022-09-01)